Coherus Biosciences Total Liabilities

Coherus Biosciences (CHRS) currently reports a total liabilities of $190M as of March 2026. That compares with $550M in the prior-year period — down 66.2% year over year. Use the charts on this page to explore Coherus Biosciences's total liabilities history and peer comparisons.

Coherus Biosciences's total liabilities decreased from $550M to $190M — a 66.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Coherus Biosciences reported $190M in total liabilities as of March 2026. That compares with $550M in the prior-year period — down 66.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Coherus Biosciences, and consider following CHRS for alerts when major investors trade the stock.

Coherus Biosciences is classified in the Healthcare sector. On total liabilities, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CHRS with unrelated industries.